GleamWall
中文EN

BLRX BioLineRx Ltd. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1498403 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-95.9%
TTM net income YoY13.0%
TTM EPS YoY100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin80.5%
Operating margin-871.8%
Net margin-680.2%
FCF margin-686.4%
EBITDA margin-829.8%

Returns

ROE-50.7%
ROA-20.1%
ROIC (approx.)-90.4%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets42.9%
Debt / equity0.00x
Current ratio1.95x
Interest coverage-8.22x

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.1%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue$1.18M$28.94M
Cost of revenue$230,000$9.26M
Gross profit$950,000$19.68M
R&D expense$8.09M$9.15M
SG&A expense$3.14M$6.32M
Operating income-$10.29M-$20.41M
Interest expense$1.25M$9.07M
Income tax$0$0
Net income-$8.03M-$9.22M
EBITDA-$9.79M-$19.98M
EPS (basic)0.00-0.01
EPS (diluted)0.00-0.01
Weighted avg. shares (diluted)2.47B1.20B
Balance sheet
Cash & equivalents$3.25M$10.44M
Receivables$46,000$2.48M
Inventory$2.15M$3.15M
Current assets$23.68M$27.10M
PP&E, netmay include right-of-use assets (IFRS)$160,000$386,000
Intangibles$16.37M$10.45M
Total assets$40.91M$38.91M
Current liabilities$12.12M$15.41M
Short-term debt$4.48M$4.48M
Total liabilities$17.56M$25.45M
Shareholders' equity$18.20M$13.46M
Cash flow statement
Operating cash flow-$8.07M-$43.87M
Capital expenditure$25,000$53,000
Free cash flow-$8.10M-$43.93M
Investing cash flow-$8.54M$29.37M
Financing cash flow$8.88M$20.66M
Depreciation & amortization$495,000$431,000
Stock-based compensation$396,000$1.14M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.